Rogoff wrote in The Economist that President Donald Trump’s trade policies may ultimately erode America’s global standing, and recommended beginning a course correction by removing trade adviser Peter Navarro.
The approval is based on positive results from a phase 3 trial, which demonstrated that Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.
The visit marks Canadian Prime Minister Mark Carney’s first in-person meeting with U.S. President Donald Trump since winning the April 28 federal election.
President Donald Trump's sweeping economic agenda combining tax breaks, spending cuts and immigration reform faces obstacles in Congress, while a major Wall Street figure raises alarm about potential market impacts.
According to Morgan Stanley's Matt Wilson, the 5,750-5,800 area — the convergence of the 200-day and 100-day moving averages — is the most critical technical test for the S&P 500 Index.
Fraser’s comments come as multiple companies have either withdrawn their full-year guidance or reduced their forecasts due to macroeconomic uncertainty.
Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services sector, raising doubts about near-term rate cuts and weighing on risk appetite.
US services sector growth slows in April. Inflationary pressures surge to a 2-year high, driven by trade tariffs. Stalling momentum and stagflation risks loom.
The Federal Reserve is expected to hold interest rates steady, even as President Donald Trump continued to pressure Chair Jerome Powell last week to slash the rates amid rising trade-related risks.
The automaker has lowered its full-year profit forecast but remains optimistic about offsetting some tariff impacts and maintaining its manufacturing investments.
